This 2018 review examines the rising prevalence of pediatric allergic diseases in China, including asthma, allergic rhinitis, and atopic eczema, correlating with rapid urbanization and lifestyle changes. Despite the increasing disease burden, pediatric allergy as a subspecialty remains underdeveloped due to the lack of formal training programs and certification. Efforts
This 2018 review article in Nutrients by Avery and Hoffmann delves into the pivotal role of selenium and its incorporation into selenoproteins in modulating immune responses. Selenium, an essential trace element, is integral to the function of 25 known human selenoproteins, many of which are involved in antioxidant defense and
This 2013 study by Boor et al. examined how rapamycin, an mTOR inhibitor, modulates the functions of human plasmacytoid dendritic cells (pDCs), which are pivotal in both innate and adaptive immunity. At clinically relevant concentrations, rapamycin significantly suppressed Toll-like receptor 7 (TLR7)-induced interferon-alpha (IFN-α) production by 64% and modestly reduced
This 2021 review article, published in International Immunopharmacology, examines the potential of low-dose naltrexone (LDN) as an adjunctive therapy in cancer treatment. The authors discuss preclinical and clinical studies indicating that LDN, administered at doses ranging from 1.5 to 4.5 mg daily, may exert antitumor effects through modulation of the
This 2015 study published in Cancer Research investigates the impact of rapamycin on antitumor immunity, particularly focusing on CD8+ T-cell responses and the efficacy of therapeutic cancer vaccines. The researchers found that rapamycin treatment impaired the expansion and function of tumor-specific CD8+ T cells, leading to reduced cytotoxic activity against
This 2017 pilot study, published in Biomedicines, explored the immunomodulatory effects of low-dose naltrexone (LDN) in fibromyalgia patients. Conducted by Parkitny and Younger at the University of Alabama at Birmingham, the study involved 10 female participants who received 4.5 mg of LDN nightly for eight weeks. The treatment led to
In this 2015 commentary, Mikhail V. Blagosklonny reflects on the potential of rapamycin as an anti-aging agent, particularly its role in rejuvenating the immune system. He discusses how rapamycin, an mTOR inhibitor, has been shown to delay aging and extend lifespan in various animal models by modulating immune function and
This 2019 review article, published in International Immunopharmacology, examines the role of the opioid growth factor (OGF)–OGF receptor (OGFr) axis in cancer therapy. OGF, identified as [Met5]-enkephalin, is an endogenous peptide that binds to OGFr to regulate cell proliferation by inhibiting DNA synthesis. The review discusses how low-dose naltrexone (LDN),
This 2014 Cochrane systematic review assessed the efficacy and safety of low-dose naltrexone (LDN) for inducing remission in Crohn’s disease. Two randomized controlled trials were included: one involving 34 adults receiving 4.5 mg/day of LDN for 12 weeks, and another with 12 pediatric patients administered 0.1 mg/kg (up to 4.5
This 2018 prospective cohort study, published in the Journal of Translational Medicine, assessed the efficacy of low-dose naltrexone (LDN) in inducing remission among therapy-refractory inflammatory bowel disease (IBD) patients. Forty-seven individuals with active Crohn’s disease or ulcerative colitis, unresponsive to standard treatments, received 4.5 mg of LDN nightly for 12
